Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

DT, Teachey; SR, Rheingold; SL, Maude; G, Zugmaier; DM, Barrett; AE, Seif; KE, Nichols; EK, Suppa; M, Kalos; RA, Berg; JC, Fitzgerald; R, Aplenc; L, Gore; SA, Grupp

doi:10.1182/blood-2013-02-485623

Public

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

Published in Blood • May 15, 2013

Authors:

Teachey DT

Rheingold SR

Maude SL

Abstract

Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with blinatumomab and other T cell-activating therapies develop cytokine release syndrome (CRS). We hypothesized that patients wi...

View

Open Access

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!